Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
CRD-1 by Merck for Myasthenia Gravis: Likelihood of Approval
CRD-1 is under clinical development by Merck and currently in Phase III for Myasthenia Gravis. According to GlobalData, Phase III...